Archive for 'The Industry' Category

Pyrimethamine Poisoning in Pakistan

By Anthony - Last updated: Wednesday, February 8, 2012

The number of dead in the wake of the substandard medicines disaster in Pakistan continues to rise with approximately 140 patients killed. Another 50 are not expected to survive. The product involved was isosorbide mononitrate tablets, commonly used in heart failure and angina, which was provided free by the Punjab Institute for Cardiology to patients […]

Nazis, concentration camps, & thalidomide

By Anthony - Last updated: Thursday, November 3, 2011

In a piece on what ever happened to the thalidomide babies Frederick Dove raises the issue of a Nazi link to thalidomide (Contergan was its German trade name) . This is important because the victims of thalidomide may then be able to leverage greater support and help for survivors. It is worth noting that German […]

Licence to print money?

By Anthony - Last updated: Thursday, November 18, 2010

A few years ago, there was concern that pharmaceutical companies were not sufficiently interested in the development of licenced drugs for rare (or “orphan”) medical conditions. Experience in the US and Japan suggested that legislation to encourage pharmaceutical manufacturers to become involved in developing so-called orphan drugs was effective. Similar legislation was passed in 1999 […]

Magical cancer drug

By Anthony - Last updated: Tuesday, October 12, 2010

Any treatment that ameliorates cancer, never mind cure it, is good news. Unequivocally. However, sometimes you have to wonder at the way in which information about new cancer treatments hits the public. First a paper is presented at a conference. Abiraterone increases median survival in currently untreatable prostate cancer by four months: “This is a […]

Are lawsuits the way to ensure drug safety?

By Anthony - Last updated: Thursday, October 7, 2010

Asks Andre Picard in the Globe and Mail. The answer is “no”. Canada and the US arguably reach for the law suit more often than Europe, but it isn’t clear that drug safety in Europe is any less effective for that. For example, despite the difference in culture, it is the US that has left […]

Patient groups and NICE

By Anthony - Last updated: Tuesday, August 24, 2010

When writing a scientific paper, one task during the process of submitting the paper is to gather up the conflicts of interest so that readers can judge if they may have introduced bias into your paper. They may not have, but all the same it is the general view that providing such information is important. […]

Clinical trial concerns in India

By Anthony - Last updated: Monday, January 5, 2009

Here’s a short film about ethical concerns in clinical trials in India produced by WEMOS which is worth watching:

Rimonabant withdrawal and conflicts of interest

By Anthony - Last updated: Thursday, October 23, 2008

The EMEA’s Committee for Medicinal Products for Human Use (CHMP) have pulled the marketing authorisation for rimonabant (Acomplia) [PDF]. This isn’t much of a surprise. What is interesting in this case is the reasoning, which not only addresses safety concerns, but also concerns about effectiveness in clinical practice (as opposed to clinical trials). Effectiveness, rather […]

Regulators, the public, and blogs

By Anthony - Last updated: Thursday, September 18, 2008

In times gone by regulatory bodies concerned with drugs were a black box. Decisions were made and conveyed to the public, with little explanation. Other concerns, that were preliminary and yet to be confirmed by further evidence might be delayed. Public engagement with regulators was minimal. For a number of years things have been changing. […]